niraparib在卵巢癌治疗中的研究进展

Research progress in niraparib in the treatment of ovarian cancer

卵巢癌是妇科3大肿瘤之一,发病率逐年上升。尽管目前对卵巢癌的治疗方法已取得长足进步,但是患者生存率仍较低,寻求更加高效低不良反应的治疗方法仍是临床医师及科研人员不懈努力的方向。近年来已在卵巢癌中进行了多种聚腺苷二磷酸核糖聚合酶[poly(ADP-ribose)polymerase,PARP]抑制剂的临床研究。niraparib为新型PARP抑制剂,也是首个应用于复发型卵巢上皮癌的靶向药物,对乳腺癌易感基因(breast cancer susceptibility gene,BRCA)野生型及突变型患者均有较好的治疗效果,与放疗及化疗联合应用也有良好效果。本文对niraparib在卵巢癌中的应用进行综述。

Ovarian cancer is one of the three major gynecological tumors, and its incidence is increasing year by year. Although the current treatment of ovarian cancer has made great progress, the survival rate of patients with ovarian cancer is still low. It is a constant direction for clinicians and researchers to look for more effective treatment with fewer side effects. In recent years, the poly（ADP-ribose） polymerase（PARP） inhibitors are more widely used in the research of ovarian cancer. Niraparib, as a new PARP inhibitor, is the first targeted drug for the treatment of recurrent ovarian epithelial cancer. Niraparib has a good therapeutic effect for breast cancer susceptibility gene（BRCA）wild type and mutant type of patients with ovarian cancer, especially when it combined with radiotherapy and chemotherapy. This article aims to summarize the application of niraparib in ovarian cancer.